These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 17848374

  • 1. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model.
    Kokai-Kun JF, Chanturiya T, Mond JJ.
    J Antimicrob Chemother; 2007 Nov; 60(5):1051-9. PubMed ID: 17848374
    [Abstract] [Full Text] [Related]

  • 2. Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice.
    Kokai-Kun JF, Chanturiya T, Mond JJ.
    J Antimicrob Chemother; 2009 Jul; 64(1):94-100. PubMed ID: 19398455
    [Abstract] [Full Text] [Related]

  • 3. In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections.
    Desbois AP, Gemmell CG, Coote PJ.
    Int J Antimicrob Agents; 2010 Jun; 35(6):559-65. PubMed ID: 20206480
    [Abstract] [Full Text] [Related]

  • 4. Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit.
    Dajcs JJ, Hume EB, Moreau JM, Caballero AR, Cannon BM, O'Callaghan RJ.
    Invest Ophthalmol Vis Sci; 2000 May; 41(6):1432-7. PubMed ID: 10798659
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus.
    Reyes N, Skinner R, Benton BM, Krause KM, Shelton J, Obedencio GP, Hegde SS.
    J Antimicrob Chemother; 2006 Aug; 58(2):462-5. PubMed ID: 16735425
    [Abstract] [Full Text] [Related]

  • 6. Lysostaphin: an antistaphylococcal agent.
    Kumar JK.
    Appl Microbiol Biotechnol; 2008 Sep; 80(4):555-61. PubMed ID: 18607587
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin.
    Placencia FX, Kong L, Weisman LE.
    Pediatr Res; 2009 Apr; 65(4):420-4. PubMed ID: 19127212
    [Abstract] [Full Text] [Related]

  • 9. In vitro and in vivo activities of echinomycin against clinical isolates of Staphylococcus aureus.
    Park YS, Shin WS, Kim SK.
    J Antimicrob Chemother; 2008 Jan; 61(1):163-8. PubMed ID: 17967852
    [Abstract] [Full Text] [Related]

  • 10. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
    Hegde SS, Skinner R, Lewis SR, Krause KM, Blais J, Benton BM.
    J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
    [Abstract] [Full Text] [Related]

  • 11. [Methicillin-resistant Staphylococcus aureus infection and its treatment in burned patients].
    Huan JN, Chen YL, Ge SD.
    Zhonghua Wai Ke Za Zhi; 1994 Apr; 32(4):244-5. PubMed ID: 7842932
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
    Sakoulas G, Moellering RC.
    Clin Infect Dis; 2008 Jun 01; 46 Suppl 5():S360-7. PubMed ID: 18462091
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis.
    Tsaganos T, Skiadas I, Koutoukas P, Adamis T, Baxevanos N, Tzepi I, Pelekanou A, Giamarellos-Bourboulis EJ, Giamarellou H, Kanellakopoulou K.
    J Antimicrob Chemother; 2008 Aug 01; 62(2):381-3. PubMed ID: 18445576
    [Abstract] [Full Text] [Related]

  • 15. Lysostaphin in treatment of neonatal Staphylococcus aureus infection.
    Oluola O, Kong L, Fein M, Weisman LE.
    Antimicrob Agents Chemother; 2007 Jun 01; 51(6):2198-200. PubMed ID: 17420212
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus.
    LaPlante KL.
    Diagn Microbiol Infect Dis; 2007 Apr 01; 57(4):413-8. PubMed ID: 17141452
    [Abstract] [Full Text] [Related]

  • 17. Effects of lysostaphin on Staphylococcus aureus infections of the mouse mammary gland.
    Bramley AJ, Foster R.
    Res Vet Sci; 1990 Jul 01; 49(1):120-1. PubMed ID: 2382049
    [Abstract] [Full Text] [Related]

  • 18. Bioluminescence and 19F magnetic resonance imaging visualize the efficacy of lysostaphin alone and in combination with oxacillin against Staphylococcus aureus in murine thigh and catheter-associated infection models.
    Hertlein T, Sturm V, Lorenz U, Sumathy K, Jakob P, Ohlsen K.
    Antimicrob Agents Chemother; 2014 Jul 01; 58(3):1630-8. PubMed ID: 24366730
    [Abstract] [Full Text] [Related]

  • 19. Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin.
    Graham S, Coote PJ.
    J Antimicrob Chemother; 2007 Apr 01; 59(4):759-62. PubMed ID: 17324959
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of ME1036 against meticillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of haematogenous pulmonary infection.
    Yanagihara K, Ohnishi Y, Morinaga Y, Nakamura S, Kurihara S, Seki M, Izumikawa K, Kakeya H, Yamamoto Y, Yamada Y, Kohno S, Kamihira S.
    Int J Antimicrob Agents; 2008 Nov 01; 32(5):401-4. PubMed ID: 18715761
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.